Dr Bianca Middleton
FRACP, Royal Australasian College of Physicians, General Paediatrics 2014; MPH, Menzies School of Health Research & Charles Darwin University, 2011; MBBS (Hons), Monash University, 2003
Dr Bianca Middleton is a paediatrician and PhD student in the Global and Tropical Health Division at Menzies School of Health Research. She is a practicing paediatrician in the Department of Paediatrics at the Royal Darwin Hospital.
Her research fields include Aboriginal child health with a particular focus on vaccines and vaccine preventable diseases, including rotavirus, influenza and SARS-CoV-2. She has experience conducting vaccine effectiveness studies and implementing Bayesian adaptive clinical trials.
Dr Middleton is currently Co-Deputy Chair of the NT Department of Health and Menzies School of Health Human Research Ethics Committee, is the NT representative for Adverse Events Following Immunisation – Clinical Assessment Network and co-author of the Diarrhoea protocol for the Remote Primary Health Care Manual.
She provides both clinical and research supervision to Advanced Trainees in General Paediatrics through the Royal Australasian College of Physicians.
The Australian Academy of Science has awarded the 2017 Douglas and Lola Douglas Scholarship to Dr Bianca Middleton for her research on improving the health of Indigenous children.
- Middleton, B.F., Danchin, M.D., Jones, M.A. et al Immunogenicity of a third scheduled dose of Rotarix in Australian Indigenous infants: a phase IV, double-blind, randomised, placebo-controlled clinical trial, The Journal of Infectious Diseases, 2022;, jiac038, https://doi.org/10.1093/infdis/jiac038
- Middleton, B.F., Danchin, M., Quinn, H., et al. Retrospective Case-Control Study of 2017 G2P Rotavirus Epidemic in Rural and Remote Australia. Pathogens 2020, 9, 790. https://doi.org/10.3390/pathogens9100790
- Middleton B.F., Jones M.A., Waddington C.S., et al. The ORVAC trial protocol: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis. BMJ Open 2019;9:e032549.http://dx.doi.org/10.1136/bmjopen-2019-032549
- Jones, M.A., Graves, T., Middleton, B. et al. The ORVAC trial: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis: a statistical analysis plan. Trials 21, 741 (2020). https://doi.org/10.1136/bmjopen-2019-032549